---
layout: default
title: Aconitum Napellus Whole Arabica Coffee Bean Arseni
parent: 僅模型預測 (L5)
nav_order: 124
evidence_level: L5
indication_count: 0
---

# Aconitum Napellus Whole Arabica Coffee Bean Arseni
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Component Homeopathic Complex (Aconitum / Nux-Vomica / Sulfur et al.): No Repurposing Predictions Available

---

## One-Sentence Summary

This candidate is a nine-ingredient mixture — Aconitum napellus, Arabica coffee bean, Arsenic trioxide, Magnesium, Oyster shell calcium carbonate, Pulsatilla vulgaris, Sepia officinalis, Strychnos nux-vomica seed, and Sulfur — whose ingredient profile is characteristic of a **homeopathic combination product**.
The TxGNN model returned **no predicted new indications** for this candidate string, and the compound carries **zero US regulatory licenses** and **no supporting clinical trial or literature evidence** within this analysis.
Evaluation cannot advance until foundational data gaps are resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available (no regulatory data found) |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — but no prediction was generated |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

No TxGNN prediction was generated for this candidate, so a formal repurposing rationale cannot be constructed at this stage.

The ingredient list is characteristic of a **classical homeopathic combination product**: Aconitum napellus (monkshood), Pulsatilla vulgaris (pasque flower), Sepia officinalis (cuttlefish ink), Strychnos nux-vomica seed, and Sulfur are among the oldest materia medica in homeopathic practice. No unified DrugBank ID or consolidated mechanism of action exists for the mixture as a whole, which is likely why the TxGNN knowledge-graph pipeline could not resolve the compound to a mappable node.

One ingredient stands out: **arsenic trioxide** is a recognised pharmaceutical agent with FDA approval for acute promyelocytic leukaemia (APL). However, its inclusion in a multi-ingredient homeopathic preparation cannot be equated with the monotherapy drug — dose, formulation, and regulatory pathway are fundamentally different. Until the product is decomposed into individual pharmacologically active constituents with confirmed doses, no mechanistic or repurposing analysis is meaningful.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## US Market Information

No US regulatory licenses found. Zero NDA / ANDA records are associated with this compound string.

---

## Safety Considerations

All standard warning and contraindication fields returned no data; please refer to the individual ingredient package inserts or product monograph for safety information.

**Important flag — arsenic trioxide component**: As a stand-alone FDA-approved pharmaceutical (brand name Trisenox), arsenic trioxide carries **Black Box Warnings** for QTc prolongation, potentially fatal cardiac arrhythmias, electrolyte abnormalities, and APL differentiation syndrome. If this combination product contains pharmacologically active doses of arsenic trioxide, those warnings apply directly and must be evaluated before any clinical use.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN model produced no repurposing predictions for this multi-component string, and the compound has no US regulatory approvals, no recorded indications, and no resolvable mechanism of action. There is no actionable repurposing signal to evaluate at this time.

**To proceed, the following is needed:**

- **Clarify product classification**: Determine whether this is a registered homeopathic product or a conventional pharmaceutical combination, and obtain the corresponding product monograph or package insert (resolves DG001 — Blocking)
- **Decompose and re-query**: Submit each of the nine ingredients individually to TxGNN to obtain per-ingredient predictions, then aggregate results
- **Obtain individual MOA data**: Retrieve DrugBank records for each component — particularly arsenic trioxide, magnesium, and calcium carbonate — to enable mechanistic analysis (resolves DG002 — High)
- **Clarify arsenic trioxide dose and form**: If the product contains pharmacologically significant arsenic trioxide, a full oncology safety evaluation (including QTc monitoring protocol) is required before any further steps
- **Assess evaluation framework fit**: If the product is confirmed homeopathic (ultra-dilute), standard drug-repurposing methodology may not be the appropriate evaluation pathway; consider referencing FDA's Homeopathic Drug Products guidance (2019) instead
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

